Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Income from Non-Controlling Interests came in at -$100.8 million in Q2 2026, down 99.32% on a YoY basis from -$14.9 billion in Q2 2025, and up 33.22% quarter-over-quarter from -$150.9 million in Q4 2025.
Analysis
Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Income from Non-Controlling Interests for 7 consecutive years, with -$100.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Non-Controlling Interests fell 99.32% year-over-year to -$100.8 million; the trailing twelve-month figure through Jun 2026 stood at -$354.7 million (down 28.08% YoY), and the FY2026 full-year result was -$98.1 million, up 46.88% from the prior year.
- Income from Non-Controlling Interests advanced to -$100.8 million in Q2 2026 per ROIV's latest filing, from -$150.9 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$22.0 million in Q2 2022 and bottomed at -$150.9 million in Q4 2025.
- Historically, Income from Non-Controlling Interests has averaged -$65.8 million across 5 years, with a median of -$50.6 million in 2025.
- The sharpest annual moves came in 2024 and 2026: Income from Non-Controlling Interests declined 4.93% in 2024, then slumped 99.32% in 2026.
- Over 5 years, Income from Non-Controlling Interests stood at -$79.2 million in 2022, then fell by 9.03% to -$86.3 million in 2023, then sank by 60.82% to -$138.9 million in 2024, then retreated by 8.67% to -$150.9 million in 2025, then jumped by 33.22% to -$100.8 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$100.8 million, -$150.9 million, and -$52.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -100.77 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -100.77 Mn |
| Dec 31, 2025 | -150.89 Mn |
| Sep 30, 2025 | -52.52 Mn |
| Jun 30, 2025 | -50.56 Mn |
| Dec 31, 2024 | -138.85 Mn |
| Sep 30, 2024 | -49.74 Mn |
| Jun 30, 2024 | -37.81 Mn |
| Dec 31, 2023 | -86.34 Mn |
| Sep 30, 2023 | -26.79 Mn |
| Jun 30, 2023 | -36.03 Mn |
| Dec 31, 2022 | -79.19 Mn |
| Sep 30, 2022 | -24.33 Mn |
| Jun 30, 2022 | -21.98 Mn |
| Dec 31, 2021 | -57.60 Mn |
| Sep 30, 2021 | -17.16 Mn |
| Jun 30, 2021 | -18.90 Mn |
| Dec 31, 2020 | -14.57 Mn |
| Sep 30, 2020 | -18.10 Mn |
| Jun 30, 2020 | -4.73 Mn |